Elena’s team had spent three years developing a broad-spectrum antiviral compound, code-named AVI-7. It worked differently from existing drugs: rather than targeting viral surface proteins (which mutate rapidly), AVI-7 attached to a host cell protein that the virus needed to replicate. In theory, this made it “resistance-proof.” But theory was not evidence.
But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning. anti virus trial
With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it. Elena’s team had spent three years developing a
This phase involved 3,500 participants across seven countries—Vietnam, Brazil, Kenya, Finland, India, South Africa, and Canada. The trial was randomized and placebo-controlled, but this time, patients came in with early flu symptoms. The endpoint: did AVI-7 shorten illness and prevent hospitalization? But the trial also revealed a serious flaw